 teniposid small-cel lung cancer random studi random studi teniposid etoposid differ activ toxic analog small-cel lung cancer sclc untreat patient sclc patient assess respons differ group respect extent diseas median age perform statu PS initi dose compound IV day week inclus patient studi dose differ toxic hematolog toxic studi overal respons complet respons CR partial respons PR CR compound median surviv month patient month patient activ singl agent sclc